Related Experiment Videos
Scleromyxedema without paraproteinemia.
Alvaro A Abarzúa1, Laura F Giesen, Mauricio O Sandoval
1Department of Dermatology, Pontificia Universidad Católica de Chile (Pontifical Catholic University of Chile), Santiago, Chile.
International Journal of Dermatology
|February 18, 2014
Summary
Thalidomide shows effectiveness in managing scleromyxedema, a rare skin condition. This treatment offers stability for patients, even those without monoclonal gammopathy, highlighting its therapeutic potential.
Area of Science:
- Dermatology
- Immunology
- Rare Diseases
Background:
- Scleromyxedema is a rare, chronic cutaneous mucinosis characterized by skin papules and indurations, often linked to monoclonal gammopathy.
- Histological findings include dermal mucin deposits and fibrosis, with variable responses to existing treatments.
Observation:
- This report details an unusual case of scleromyxedema in a young patient lacking monoclonal gammopathy.
- The patient was treated with thalidomide, an immunomodulatory drug.
Findings:
- Treatment with thalidomide resulted in patient stability, maintaining existing skin injuries.
- Thalidomide demonstrated effectiveness in managing scleromyxedema, even in the absence of monoclonal gammopathy.
Implications:
- Thalidomide presents a viable therapeutic option for scleromyxedema patients, particularly those without monoclonal gammopathy.
- Periodic monitoring for monoclonal components is recommended for patients with scleromyxedema.
- Further clinical studies are needed to establish long-term safety and efficacy of thalidomide for scleromyxedema.
Related Concept Videos
01:24Graves Disease II: Pathophysiology
26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
01:28Graves' Disease I: Introduction
23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
01:24Nephrotic Syndrome I : Introduction
1.2K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.2K
01:26Cushing Syndrome I: Introduction
36
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
36
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:19Cushing Syndrome II: Pathophysiology
24
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24